Data presented at CROI 2026 on chronic hepatitis B and hepatitis E.

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus  Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON | Bitget crypto news!

AT-587 and AT-2490 were 30–150x more potent against hepatitis E than sofosbuvir or ribavirin in vitro, with no toxicity; Atea plans Phase 1 mid-2026.

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus  Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON,…

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, […]

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus  Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON,…

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. | Bitget crypto news!

Health News: In India, millions of people are living with hepatitis B or C and don’t even know it. You could feel completely fine, go to work every day, eat normal.

Aim Hepatitis E virus (HEV) is an emerging cause of acute hepatitis in developed countries. Older adults may be prone to symptomatic disease due to age-related vulnerability or underlying conditions. Limited data exist regarding risk factors, clinical outcomes, and liver fibrosis markers in…

Foodborne viruses such as norovirus, hepatitis A, and hepatitis E remain difficult to control because they spread through contaminated water, infected food handlers, and animal reservoirs, and they resist many standard food safety measures. The FAO–WHO experts conclude that prevention, safe water, sanitation, hygiene, and keeping sick workers away from food is far more effective […]

PHNOM PENH — When floodwaters rise in Cambodia’s cities, they do more than inundate streets and homes. …

Atea Pharmaceuticals (NASDAQ:AVIR) used its presentation at the 44th Annual JPMorgan Healthcare Conference to provide updates on its global Phase 3 program for hepatitis C (HCV) and to outline early progress in a new hepatitis E (HEV) antiviral program. CEO and founder J.P. Sommadossi was joined in

The World Health Organisation (WHO) has released its 2023 Essential Diagnostics List, which includes key updates to aid in the global management of various health conditions. Notably, the list now incorporates essential tests for hepatitis E virus (HEV) and personal glucose monitoring devices for diabetes, aiming to improve outbreak management and enhance disease control.

Dr. Reddy’s launches Hevaxin, India’s first DCGI-approved vaccine, to combat the deadly waterborne Hepatitis E virus.

Dr. Reddy’s Laboratories has introduced Hevaxin, a reco […]

Dr. Reddy’s Laboratories announced the launch of Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection in India.  Hevaxin is the only vaccine approved by […]

Dr. Reddy’s Laboratories has announced the launch of Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection in India, marking a significant expansion of the company’s preventive healthcare portfolio.​ Hevaxin is currently the only vaccine approved by the Drug Controller General of India (DCGI) for active immunisation against HEV infection […]

Dr. Reddy’s Laboratories has launched Hevaxin, a novel vaccine for preventing Hepatitis E in India, targeting adults aged 18-65. This vaccine promises long-lasting immunity and supports the National Viral Hepatitis Control Programme.

The company said Hevaxin is the only hepatitis E vaccine approved by the Drug Controller General of India (DCGI) and is indicated for active immunisation against HEV infection